IP Library Granted Patent US 7,052,832
Granted Patent B2
US 7,052,832 · App. 09/985,756 · Granted May 30, 2006

Methods for the treatment of cellular proliferative disorders

Assignee: Oncolytics Biotech Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,052,832
App. No.
09/985,756
Granted
May 30, 2006
Kind
B2
Abstract

The present invention relates to methods of identifying the susceptibility of cells to reovirus infection by measuring constitutive ras-MAP signaling. The invention also pertains to methods using reovirus for the treatment of cellular proliferative disorders, and particularly cellular proliferative disorders wherein the proliferating cells exhibit constitutive MAPK phosphorylation, in mammals. In particular, the methods provide for reovirus treatment of mammals to treat proliferative disorders which include breast tumors, a subset of tumors in which mutation of the ras gene is not believed to play a significant role.

Claims (10)

1. A method of determining susceptibility of a cell to reovirus infection by measuring constitutive ras-MAP signaling in said cell, wherein the presence of said constitutive signaling indicates susceptibility to infection by reovirus.

2. The method of claim 1 wherein the ras-MAP signaling is measured by determining the state of phosphorylation of MAP kinase.

3. The method of claim 2 wherein the state of MAP kinase phosphorylation is determined using an antibody specific for phosphorylated MAP kinase.

4. The method of claim 1 wherein the cell is comprised in a biological sample collected from a mammal suspected of having a proliferative disorder.

5. The method of claim 4 wherein the proliferative disorder is neurofibromatosis.

6. The method of claim 4 wherein the proliferative disorder is a solid neoplasm.

7. The method of claim 4 wherein the proliferative disorder is selected from the group consisting of lung cancer, prostate cancer, colorectal cancer, thyroid cancer, renal cancer, adrenal cancer, liver cancer, pancreatic cancer, breast cancer and central and peripheral nervous system cancer.

8. The method of claim 4 wherein the proliferative disorder is breast cancer.

9. The method of claim 4 wherein the mammal is selected from the group consisting of dogs, cats, sheep, goats, cattle, horses, pigs, mice, non-human primates, and humans.

10. The method of claim 4 wherein the mammal is human.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME AND ADDRESS PREVIOUSLY RECORDED ON REEL 012296, FRAME 0672. ASSIGNOR HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST. Recorded Feb 16, 2006
From: COFFEY, MATTHEW C.
To: ONCOLYTICS BIOTECH INC.
Reel/Frame 017337/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2001
From: COFFEY, MATTHEW C.
To: ONCOLYTICS BIOTECH, INC.
Reel/Frame 012296/0672 →
Continuity (2)
Provisional Application 6024672800 · Nov 9, 2000
Related Publication 20020086284A1 · Jul 4, 2002